Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Disease…

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Pancreatic Cancer Action Network

Questions About Clinical Trials? The PanCAN Patient Services Team Can Help

The PanCAN Patient Services team is here for patients and their loved ones as they navigate clinical trials. Our Case Managers offer personal, one-to-one support at every step of the search and ...

PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program

The company confirmed the publication of its successful clinical case series in Frontiers in Immunology, a peer-reviewed scientific journal, and received confirmation from the U.S. Food and Drug ...

Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge and Establishes New Oncology Center of Excellence

LumaBridge will form the foundation of Avance's global Oncology Center of Excellence. The LumaBridge team brings experienced oncology leadership, strong U.S. operational capabilities, and a proven ...
MacTech

iPhones, Apple Watches used in study to track Parkinson’s disease symptoms

Rune Labs, which specializes in precision medicine for Parkinson’s disease (PD), has launched of a clinical program with Parkinson’s Foundation. The goal is to “accelerate the discovery of genetic and ...
PharmiWeb

Volastra Therapeutics Expands Clinical Development Program Following Encouraging KIF18A Inhibitor Data and Appoints New Chief Medical Officer to Lead Clinical Strategy

Expansion of lead KIF18Ai program in lung, head and neck cancers following early positive resultsGenetic biomarker signatures show early correlation with KIF18Ai clinical responseCompany reports ...
Nasdaq

Entrada Therapeutics Authorizes Phase 1/2 Clinical Trial for ENTR-601-44 to Treat Duchenne Muscular Dystrophy, On Track for Q2 2025 Initiation

Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...